SCHEMBL1714908

SCHEMBL1714908

CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCCO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AR P10275 15/20 0.82
PGR P06401 1/20 0.82
HDAC1 Q13547 4/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453440 1.00 AR (0.82) ARPGRHDAC1
SCHEMBL3868030 0.99 AR (0.80) ARPGRHDAC1
SCHEMBL8517259 0.99 AR (0.80) ARPGRHDAC1
SCHEMBL2693558 0.97 AR (0.81) ARPGRHDAC1
SCHEMBL30291848 0.93 AR (0.77) ARPGRHDAC1
SCHEMBL4020463 0.93 AR (0.77) ARPGRHDAC1
SCHEMBL7779111 0.91 AR (0.78) ARPGRHDAC1
SCHEMBL8865594 0.91 AR (0.78) ARPGRHDAC1
SCHEMBL20003386 0.90 AR (0.80) ARPGRHDAC1
Ru-58841 SCHEMBL29372187 0.90 AR (1.00) ARPGRHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0580459-B1 Substituted Phenylimidazolidins, their use as medicaments and their pharmaceutical compositions containing them HOECHST MARION ROUSSEL INC (FR) 2001-03-28 EP claimed
US-RE35956-E Phenylimidazolidines having antiandrogenic activity ROUSSEL UCLAF (FR) 1998-11-10 US claimed
US-5627201-A Phenylimidazolidines having antiandrogenic activity ROUSSEL UCLAF (FR) 1997-05-06 US claimed
US-5411981-A Phenylimidazolidines having antiandrogenic activity ROUSSEL UCLAF (FR) 1995-05-02 US claimed
EP-0580459-A1 Substituted Phenylimidazolidins, process for their preparation, their use as medicaments and their pharmaceutical compositions containing them ROUSSEL UCLAF (FR) 1994-01-26 EP claimed
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-30 US disclosed
US-20240132452-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-04-25 US disclosed
US-20230109968-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-13 US disclosed
EP-3970721-A1 DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-23 EP disclosed
US-20210238145-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-05 US disclosed
US-20210238145-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-05 US disclosed
US-20200079741-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-03-12 US disclosed
EP-0580459-B1 Substituted Phenylimidazolidins, their use as medicaments and their pharmaceutical compositions containing them HOECHST MARION ROUSSEL INC (FR) 2001-03-28 EP disclosed
US-6162444-A Cosmetic or pharmaceutical compositions HOECHST MARION ROUSSEL (FR) 2000-12-19 US disclosed
US-RE35956-E Phenylimidazolidines having antiandrogenic activity ROUSSEL UCLAF (FR) 1998-11-10 US disclosed
US-5656651-A DETECTING TUMOR CELLS BIOPHYSICA INC. (US) 1997-08-12 US disclosed
US-5627201-A Phenylimidazolidines having antiandrogenic activity ROUSSEL UCLAF (FR) 1997-05-06 US disclosed
EP-0671156-A1 Cosmetic or pharmaceutical compositions containing liposomes ROUSSEL UCLAF (FR) 1995-09-13 EP disclosed
US-5411981-A Phenylimidazolidines having antiandrogenic activity ROUSSEL UCLAF (FR) 1995-05-02 US disclosed
EP-0580459-A1 Substituted Phenylimidazolidins, process for their preparation, their use as medicaments and their pharmaceutical compositions containing them ROUSSEL UCLAF (FR) 1994-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132452-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG AR 2/4885PGR 404/4885HDAC1 183/4885
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG AR 2/4885PGR 404/4885HDAC1 183/4885
US-20200079741-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG AR 2/4885PGR 404/4885HDAC1 183/4885
US-20230109968-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG AR 2/4885PGR 404/4885HDAC1 183/4885
US-20210238145-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG AR 2/4885PGR 404/4885HDAC1 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.